- Home
- ABTS vs SBFM Comparison
ABTS vs SBFM Comparison
Compare ABTS & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABTS
- SBFM
- Stock Information
- Founded
- ABTS 2010
- SBFM 2006
- Country
- ABTS Hong Kong
- SBFM United States
- Employees
- ABTS N/A
- SBFM N/A
- Industry
- ABTS Computer Software: Programming Data Processing
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- ABTS Technology
- SBFM Health Care
- Exchange
- ABTS Nasdaq
- SBFM Nasdaq
- Market Cap
- ABTS 4.6M
- SBFM 4.9M
- IPO Year
- ABTS N/A
- SBFM N/A
- Fundamental
- Price
- ABTS $2.47
- SBFM $1.55
- Analyst Decision
- ABTS
- SBFM Strong Buy
- Analyst Count
- ABTS 0
- SBFM 1
- Target Price
- ABTS N/A
- SBFM $15.00
- AVG Volume (30 Days)
- ABTS 22.8K
- SBFM 4.3M
- Earning Date
- ABTS 12-31-2024
- SBFM 05-19-2025
- Dividend Yield
- ABTS N/A
- SBFM N/A
- EPS Growth
- ABTS N/A
- SBFM N/A
- EPS
- ABTS N/A
- SBFM N/A
- Revenue
- ABTS $5,343,888.00
- SBFM $34,874,283.00
- Revenue This Year
- ABTS N/A
- SBFM $192.48
- Revenue Next Year
- ABTS N/A
- SBFM N/A
- P/E Ratio
- ABTS N/A
- SBFM N/A
- Revenue Growth
- ABTS 3970.66
- SBFM 44.75
- 52 Week Low
- ABTS $0.25
- SBFM $1.17
- 52 Week High
- ABTS $4.19
- SBFM $33.60
- Technical
- Relative Strength Index (RSI)
- ABTS 56.10
- SBFM 44.81
- Support Level
- ABTS $1.75
- SBFM $1.17
- Resistance Level
- ABTS $2.45
- SBFM $1.59
- Average True Range (ATR)
- ABTS 0.41
- SBFM 0.19
- MACD
- ABTS 0.02
- SBFM 0.03
- Stochastic Oscillator
- ABTS 74.78
- SBFM 52.84
About ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.